Inovio pharmaceuticals stock.

U.S.: Nasdaq. Add to Watchlist. INO. About Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious ...Inovio Pharmaceuticals. Market Cap. $111M. Today's Change. (2.77%) $0.01. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ...Find the latest analyst research for Inovio Pharmaceuticals, Inc. Common Stock (INO) at Nasdaq.com.10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous …The latest closing stock price for Inovio Pharmaceuticals as of November 17, 2023 is 0.43. The all-time high Inovio Pharmaceuticals stock closing price was 191.04 on March 03, 2000. The Inovio Pharmaceuticals 52-week high stock price is 2.17, which is 404.7% above the current share price. The Inovio Pharmaceuticals 52-week low stock price is …

The average trading volume of INO on November 28, 2023 was 3.45M shares. INO) stock’s latest price update. Inovio Pharmaceuticals Inc (NASDAQ: INO)’s stock price has decreased by -3.07 compared to its previous closing price of 0.41. However, the company has seen a -5.38% decrease in its stock price over the last five trading sessions.Nov 28, 2023 · 52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.

Nov 9, 2021 · FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 ... Shares of Inovio Pharmaceuticals ... Inovio's stock closed at $1.56 on Friday, then opened on Monday at $1.63. its stock rose to as high as $1.865 shortly before the close and finished the day at ...

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 0.40, with a high estimate of 0.40 and a low estimate of 0.40. The ... The stock price for . Inovio Pharmaceuticals (NASDAQ: INO) is $0.4205 last updated Today at November 28, 2023 at 12:50 AM UTC. Q Does Inovio Pharmaceuticals (INO) pay a dividend?Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2021 and 2020Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 0.40, with a high estimate of 0.40 and a low estimate of 0.40. The ... INO | Complete Inovio Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

A class-action lawsuit claims that pharmaceutical company Inovio deceived the public about developing a COVID-19 vaccine, leading its stock to rise and then crash. Patrick McDermid v. Inovio Pharmaceuticals Inc. et al. Plaintiffs submitted a motion to certify the class action on Thursday, claiming thousands of investors were affected.

Legal Name Inovio Pharmaceuticals, Inc. Stock Symbol NASDAQ:INO. Company Type For Profit. Contact Email [email protected]. Phone Number 267-440-4200. INOVIO is a biotechnology company focused on rapidly …

Nov 30, 2023 · Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... Morningstar Financial Research conducts Analysis on Markets, Mutual Fund, Stocks and ETFs through Investment Data and News.The stock price of Inovio Pharmaceuticals (NYSE: INO), a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, reached its 52-week high levels of ...Pennsylvania-based Inovio Pharmaceuticals is a biotechnology business with a focus on DNA-based medicine. During the onset of the COVID-19 crisis, some traders bought INO stock as a bet on Inovio ...Find the latest Inovio Pharmaceuticals, Inc. (INO.MX) stock quote, history, news and other vital information to help you with your stock trading and investing.WebINOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program 10-10 - 1 view Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) 08-09 - 1 view Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive …

As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to help save and protect lives worldwide. The company is focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases, cancer, and diseases associated with HPV.Mar 1, 2023 · As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and ... Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2021 and 2020Nov 29, 2023 · According to the issued ratings of 1 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 1 hold rating for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $2.00 with a high price target of $2.00 and a low price target of $2.00.

Nov 8, 2022 · As of September 30, 2022, INOVIO had 249.5 million common shares outstanding and 268.7 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported ...

At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Inovio Pharmaceuticals Inc. If you are looking for stocks with good return, Inovio Pharmaceuticals Inc stock can be a bad, high-risk 1-year investment option. Second Quarter 2023 Financial Results. Cash, Cash Equivalents and Short-term Investments: As of June 30, 2023, cash, cash equivalents and short-term investments were $194.9 million compared to ...WebInovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021plymouth meeting, pa., june 23, 2023 (globe newswire) - inovio (nasdaq:ino) has released the following pursuant to an order of the united states district court eastern district of pennsylvania: united states district court eastern district of pennsylvania in re inovio pharmaceuticals, inc. derivative litigation lead case no. 2:20-cv-01962-gjp notice of …Shares of Inovio Pharmaceuticals (INO-4.71%) ... In the Tweet, Citron Research claims Inovio's stock will fall back to $5, which would be a significant drop from its current levels. The biotech's ...3 Jan 2023 ... This could mean hype has come out of the stock because the bottom line is concerning investors. Generally speaking investors would consider ...As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.Inovio Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 5 hold ratings, and 1 sell ratings. What was the 52-week low for ... As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.The latest closing stock price for Inovio Pharmaceuticals as of November 17, 2023 is 0.43. The all-time high Inovio Pharmaceuticals stock closing price was 191.04 on March 03, 2000. The Inovio Pharmaceuticals 52-week high stock price is 2.17, which is 404.7% above the current share price. The Inovio Pharmaceuticals 52-week low stock price is …

If You Invested $1,000 in Inovio Pharmaceuticals’s IPO, This Is How Much Money You'd Have Now. ... Right now, though, the stock looks like a risky coronavirus play at best.

As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ... Nov 30, 2023 · Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... First Quarter 2023 Financial Results. INOVIO reported total revenue of $115,000 for the three months ended March 31, 2023, compared to $199,000 for the same period in 2022. Total operating ...Web10 stocks we like better than Inovio Pharmaceuticals When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock ...May 15, 2023 · Inovio Pharmaceuticals (INO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ... Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...On March 1, Inovio Pharmaceuticals will release figures for the most recent quarter. Wall Street analysts predict losses per share of $0.168. Watch Inovio Pharmaceuticals stock price in real-time ...if you purchased or acquired inovio pharmaceuticals, inc.(“inovio”) common stock from february 14, 2020 through august 10, 2020, inclusive (the “class”), you could receive a payment from a ...While many coronavirus stocks soared to record highs over the past year, shares of Inovio Pharmaceuticals ( INO -5.75%) are down nearly 50% over the past 12 months. The company has not advanced ...Web

Stocks INO Overview Inovio Pharmaceuticals Inc. U.S.: Nasdaq About Inovio Pharmaceuticals Inc. See Full Profile Average price target from ratings: $ Full Ratings …The Inovio Pharmaceuticals stock price gained 0.96% on the last trading day (Friday, 1st Dec 2023), rising from $0.394 to $0.398. During the last trading day ...The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ... Instagram:https://instagram. oanda vs forex.comwhat are safe stocks to invest incash account webulltrading taxes Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 match stock forecastcai3 stock 52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today. beyond meat stcok Inovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $9.15 million ...Find the latest Inovio Pharmaceuticals, Inc. (INO) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Contact Us U.S. markets close in 3 hours 37 minutes +233.26(+0.65%) +40.71 Russell 2000 +40.80(+2.26%) +0.37(+0.49%) Gold (+1.13%) Inovio Pharmaceuticals, Inc. (INO) NasdaqCM - NasdaqCM Real Time...